Background Mycoplasma pneumoniae strains with resistance to macrolides have been spreading worldwide. Here, we aimed to clarify which antimicrobial agent is a better treatment for patients with M. pneumoniae pneumonia in a setting with large epidemics of macrolide resistance. Methods Adult patients hospitalized with laboratory-confirmed M. pneumoniae pneumonia from 2010 to 2013 were identified from the Japanese Diagnosis Procedure Combination national database. Drug switching, length of stay (LOS), 30-day mortality, and total costs for patients who underwent macrolide, quinolone, and tetracycline therapy were compared using propensity score analyses. Results Eligible patients (N = 1650) from 602 hospitals were divided into the macrolide group (n = 508), quinolone group (n = 569), or tetracycline group (n = 573). We found that 52.8%, 21.8%, and 38.6% of patients in the macrolide, quinolone, and tetracycline groups, respectively, had to switch drugs (P
CITATION STYLE
Tashiro, M., Fushimi, K., Kawano, K., Takazono, T., Saijo, T., Yamamoto, K., … Izumikawa, K. (2017). Comparison of Efficacy of Antimicrobial Agents among Hospitalized Patients with Mycoplasma pneumoniae Pneumonia in Japan during Large Epidemics of Macrolide-Resistant M. pneumoniae Infections: A Nationwide Observational Study. Clinical Infectious Diseases, 65(11), 1837–1842. https://doi.org/10.1093/cid/cix695
Mendeley helps you to discover research relevant for your work.